Valvular & structural heart diseaseCohort study

Transcatheter heart valve explant with infective endocarditis-associated prosthesis failure and outcomes: the EXPLANT-TAVR international registry

Eur Heart JPublished

  • Retrospective cohort study
  • international registry
  • 44 sites

Authors' conclusion

In the EXPLANT-TAVR registry, patients undergoing THV explant for IE had higher 30-day and 1-year stroke rates and longer intensive care unit and hospital stays. Moreover, patients undergoing THV explant for IE had a higher 3-year mortality rate, which did not reach statistical significance given the relatively small sample size of this unique cohort and the reduced number of events.

Study context

Population
Patients undergoing surgical THV explant, EXPLANT-TAVR registry, 2011–2022
Participants
372 patients
Exposure
THV explant for infective endocarditis (IE) vs for other bioprosthetic valve dysfunction (BVD)
  • IEn = 184
  • BVDn = 188reference

Main finding

As reported in the abstract

Stroke · 30 days and 1 year

Stroke at 30 days

P = 0.032

Stroke at 1 year

P = 0.010

Longer ICU and hospital stays with IE
P < 0.05

Observational data: associations, not effects.

Further findings

Mortality · 3 years postsurgery · Kaplan-Meier, not significant

P = 0.16

Adjusted mortality, entire cohort · in-hospital, 30 days, 1 year

In-hospital mortality
12.1%
30-day mortality
16.1%
1-year mortality
33.8%
No significant differences between groups

Original publication

Transcatheter heart valve explant with infective endocarditis-associated prosthesis failure and outcomes: the EXPLANT-TAVR international registry. Eur Heart J. Published 31 May 2024. doi:10.1093/eurheartj/ehae292

Summarised from the published abstract; every number is checked against it